Approximately 60,000 Minnesotans live with epilepsy and one in three has treatment-resistant seizures. Here is what the clinical evidence says about CBD for seizures, how Epidiolex compares to dispensary products, critical drug interactions with anti-epileptic medications, and how to qualify for the medical cannabis program.

Migraines affect roughly 850,000 Minnesotans. Here is what clinical research says about cannabis for acute migraine relief and prevention, including drug interactions with triptans, beta-blockers, topiramate, and valproate, and how to qualify for the medical cannabis program.

Parkinson's disease is an explicit qualifying condition for Minnesota's medical cannabis program. This 2026 guide covers the clinical evidence for tremor, REM Sleep Behavior Disorder, and pain, along with critical drug interactions with levodopa, MAO-B inhibitors, and dopamine agonists — and why CBD-dominant products are the safest starting point for most Parkinson's patients.